GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management: Biochemical Mechanisms, Clinical Efficacy, and Translational Implications

Mercy Latricia

Department of Pharmacognosy Kampala International University Uganda

Email: atricia.mercy@studwc.kiu.ac.ug

ABSTRACT

Combination therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors) has emerged as a strategic approach for glycemic control, weight management, and cardiovascular risk modification in type 2 diabetes (T2D). The mechanistic complementarity of incretin-based signaling and renal glucose excretion offers potential synergistic benefits beyond monotherapy, but the magnitude, consistency, and safety of such synergy require critical appraisal. This paper aimed to synthesize mechanistic, analytical, clinical, and translational evidence on GLP-1 RA and SGLT2 inhibitor combination therapy in T2D, identify optimal clinical contexts, and delineate gaps warranting future research. A structured literature search of electronic databases (PubMed, Embase, ClinicalTrials.gov) for peer‑reviewed studies and guidelines from 2010 to 2024 was conducted, prioritizing randomized controlled trials, meta-analyses, and high‑quality observational studies. Inclusion criteria encompassed adult T2D patients treated with GLP‑1 RAs in combination with SGLT2 inhibitors, with reporting on glycemic, weight, cardiovascular, and safety outcomes. Across trials, combination therapy produced greater reductions in HbA1c and weight versus either agent alone, with heterogeneous effects on blood pressure and lipids. Cardiovascular and renal outcomes were broadly favorable, though event rates and duration varied. Safety signals included increased gastrointestinal symptoms and, less consistently, risk of hypoglycemia in certain regimens, with preserved or improved renal function in most cohorts. Crucial interactions include additive glycemic effects, potential bile acid–mediated metabolic modulation, and potential attenuation of GLP‑1 RA–related gastrointestinal intolerance by dose-titration strategies. GLP‑1 RA and SGLT2 inhibitor combination therapy offered synergistic metabolic and cardiometabolic benefits in select T2D populations, particularly where weight reduction and cardiovascular risk mitigation are priorities, but patient selection, sequencing, and monitoring strategies must be individualized, given heterogeneity in responses and safety profiles.

Keywords: GLP-1 receptor agonist, SGLT2 inhibitor, Combination therapy, Type 2 diabetes, Glycemic control.

CITE AS: Muhindo Edgar (2026). GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management: Biochemical Mechanisms, Clinical Efficacy, and Translational Implications. IAA Journal of Biological Sciences 14(1):55-59. https://doi.org/10.59298/IAAJB/2026/1415559